Full history for every metric is available with a Kvantra account
Gamida Cell Ltd. (GMDA)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Operating profit | $m | -73 | -33 | |||||
| Net profit | $m | -53 | -34 | -76 | -92 | -154 | -63 | -22 |
| EPS reported | $ | -0.57 | -0.25 | |||||
| Operating cashflow per share | $ | -0.53 | -0.53 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -0.54 | -0.54 | |||||
| Free cash flow | $m | -80 | -79 | |||||
| Net debt | $m | 30 | 50 | |||||
| Book value equity | $m | -3 | - | |||||
| Book value per share | $ | -0.02 | - | |||||
| Number of shares | m | 148.58 | 152.71 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -20.79 | -1.65 | |||||
| P/S LTM | x | 34.37 | 1.62 | |||||
| P/FCF LTM | x | -0.76 | -0.05 | |||||
| EV/EBITDA LTM | x | -1.83 | -0.73 | |||||
| EV/Sales LTM | x | 54.77 | 20.44 | |||||
| Earnings Yield LTM | % | -102.74% | -1296.6% | |||||
| FCF Yield | % | -130.80% | -1830.0% | |||||
| Quality | ||||||||
| ROE | % | 2136.2% | 1148.3% | |||||
| ROIC | % | -86.17% | -86.17% | |||||
| Operating margin | % | -4094.1% | -4094.1% | |||||
| Gross margin | % | -94.96% | -94.96% | |||||
| FCF/Sales | % | -4495.6% | -4495.6% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.97 | -1.02 | |||||
| Net Debt/EBITDA | x | -0.68 | -0.68 | |||||
| EBIT/Net interest | x | -9.63 | -9.63 | |||||
| Net debt/market cap | % | 48.82% | 1160.3% | |||||
| Net debt/Equity | x | -10.15 | - | |||||
| Gross debt/equity | x | -28.13 | - | |||||
Company overview
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Gamida Cell Ltd. (GMDA)
Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free